GLP-1 receptor drugs for Atherosclerotic Cardiovascular Disease

6 tracked GLP-1 receptor drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the GLP-1 receptor page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.

5 approved / phase 41 Phase 3

Head-to-head evidence: Liraglutide (Victoza) vs Semaglutide (Ozempic) · Liraglutide (Victoza) vs Semaglutide (Wegovy) · dulaglutide vs Liraglutide (Victoza) · Semaglutide (Ozempic) vs Semaglutide (Rybelsus) · Semaglutide (Ozempic) vs Semaglutide (Wegovy) · dulaglutide vs Semaglutide (Ozempic)

The roster

← all GLP-1 receptor drugs